Skip to main content

Market Overview

Eli Lilly, Innovent Biologics' Sintilimab Injection Receives China Approval For A Type Of Lung Cancer

  • Eli Lilly and Company (NYSE: LLY) and its collaborating partner Innovent Biologics Inc (OTC: IVBXF) has announced that the National Medical Products Administration (NMPA) of China has approved the supplemental marketing application seeking approval for TYVYT (sintilimab injection) in combination with pemetrexed and platinum chemotherapy as first-line therapy for people with nonsquamous non-small cell lung cancer.
  • This is the second approved indication of TYVYT in China, following the first approved indication by the NMPA in December 2018 to treat relapsed or refractory classical Hodgkin's lymphoma after at least two lines of systemic chemotherapy.
  • Price Action: LLY shares closed 2.75% lower at $197.56 on Tuesday.

Related Articles (LLY + IVBXF)

View Comments and Join the Discussion!

Posted-In: China NMPA Non-Small Cell Lung CancerBiotech News General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at